Table 1 Baseline characteristics of participants

Female (%)

17 (24.3)

6 (18.8)

3(17.6)

Age, years

59 (51–69)

57 (47–68)

55 (44–64)

BMI, kg/ m²

24.9 ± 3.6

25.2 ± 3.9

26.5 ± 3.6

Smoker (%)

42 (60.0)

18 (56.3)

13 (76.5)

Hypertension (%)

43 (61.4)

23 (71.9)

9 (52.9)

Diabetes (%)

22 (31.4)

15 (46.9)

6 (35.3)

CKD (%)

6 (8.6)

5 (15.6)

2 (11.8)

AFL/Af (%)

7 (10.0)

3 (9.4)

2 (11.8)

WBC count, × 10⁹/L

9.1 (7.2–12.2)

9.8 (8.4–11.7)

9.3 (7.7–16.8)

Hemoglobin, g/ L

145 ± 16

147 ± 18

138 ± 20

PLT count, × 10⁹/L

223 (183–280)

261 (218–282)

240 (212–286)

FPG, mmol/L

5.9 (5.0–6.8)

5.6 (5.0–10.0)

6.8 (5.7–8.0)

HbA1c, %

6.6 ± 1.5

7.2 ± 1.7

6.7 ± 1.1

D-dimer, ng/mL

91 (58–159)

127 (53–343)

113 (67–264)

CRP, mg/L

4.7 (0.5–18.6)

9.9 (0.5–41.4)

11.2 (3.2–42.1)

BNP, pg/mL

151 (63–463)

290 (170–901)

625 (167–1534)

LDL-C, mmol/L

2.69 (2.21–3.62)

2.72 (2.41–3.20)

2.67 (2.09–3.47)

Triglyceride, mmol/L

1.33 (0.99–2.02)

1.38 (0.93–1.88)

1.57 (0.82–1.78)

Creatinine, μmol/L

78 (62–98)

79.5 (66.0–97.3)

87 (68–101)

Therapy

 Aspirin (%)

69(96.6)

31(96.9)

16(94.1)

 Clopidogrel (%)

66(94.3)

32(100)

16(94.1)

 Ticagrelor (%)

4(5.7)

0(0)

0(0)

 ACEi (%)

34(48.6)

14(43.8)

4(23.5)

 ARB (%)

15(21.4)

11(34.4)

8(47.1)

 β-blocker(%)

55(78.6)

28(87.5)

15(88.2)

 Statin (%)

69(98.6)

32(100)

17(100)

 Trimetazidine (%)

3(4.3)

1(3.1)

1(5.9)